JP Nadda Launches NIPER Medicinal Succulents Garden, Reviews research ecosystem

During the visit, Shri Nadda reviewed NIPER’s strategic vision, research priorities, and innovation roadmap, with a detailed presentation by Prof. Dulal Panda, Director, NIPER Mohali.

In a strong reaffirmation of India's ambition to become a global leader in biopharmaceutical innovation, Union Minister for Chemicals & Fertilizers and Health & Family Welfare Shri Jagat Prakash Nadda visited the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, where he inaugurated the NIPER Medicinal Succulents Garden and reviewed the institute's expanding research ecosystem.

The visit highlighted the Government's strategic focus on strengthening pharmaceutical research, fostering innovation, and building a self-reliant biopharma sector, aligned with the vision of Aatmanirbhar Bharat.

Focus on Cutting-Edge Biopharmaceutical Research

During the visit, Shri Nadda reviewed NIPER's strategic vision, research priorities, and innovation roadmap, with a detailed presentation by Prof. Dulal Panda, Director, NIPER Mohali.

The institute showcased its Centres of Excellence, with advanced research in:

• Biopharmaceuticals and biologics

• Emerging therapeutic domains

• Technology transfer and commercialization pathways

These initiatives position NIPER as a key contributor to India's growing pharmaceutical innovation ecosystem.

Government Push for Global Leadership in Pharma

Addressing faculty, researchers, and students, Shri Nadda emphasized India's commitment to becoming a global hub for pharmaceutical and biopharmaceutical manufacturing, particularly in critical areas such as:

• Active Pharmaceutical Ingredients (APIs)

• Key Starting Materials (KSMs)

• Synthesis intermediates

• Biologics and advanced therapies

He underscored the importance of robust research infrastructure, assuring continued policy support and funding to accelerate innovation and execution.

The Minister also commended NIPER's role in producing industry-ready professionals, vital for sustaining India's leadership in the global pharma sector.

From Research to Real-World Impact: Call for Translational Innovation

In a key policy insight, Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, emphasized the need to bridge the gap between academic research and industrial application.

He called for:

• Stronger industry collaboration and partnerships

• Enhanced technology transfer mechanisms

• Incentive-based reforms to reward externally funded research

Importantly, he stressed a shift from "paper patents" to real-world commercialization, urging institutions to focus on innovations that deliver tangible societal and economic impact.

Driving the Biopharma SHAKTI Mission

Prof. Dulal Panda highlighted NIPER's active contribution to the Government's Biopharma SHAKTI mission, with cutting-edge work in:

• Cell and gene therapies

• Biosimilars

• Medical devices

• AI-driven pharmacoinformatics

• Advanced drug delivery systems

To meet evolving industry demands, the institute has also introduced new Master's programmes in Biopharmaceuticals and Regulatory Affairs, aimed at building a future-ready workforce.

Technology Showcase Highlights Innovation Ecosystem

The visit culminated in a Technology Showcase at the Convention Centre, where the Minister reviewed:

• Research prototypes and innovations

• Industry collaborations

• Patent portfolios

• Clinical trial initiatives

The showcase demonstrated NIPER's growing emphasis on translational research and commercialization, bridging academia and industry.

Strengthening India's Pharmaceutical Ecosystem

India is already one of the world's largest suppliers of generic medicines, contributing significantly to global healthcare. With increasing focus on high-value biopharmaceuticals and advanced therapies, institutions like NIPER are expected to play a pivotal role in:

• Enhancing innovation capacity

• Reducing import dependence

• Boosting export competitiveness

A Step Toward Self-Reliance and Global Competitiveness

The visit underscores the Government of India's sustained commitment to:

• Strengthening pharmaceutical education and research

• Promoting innovation-driven growth

• Building a robust, self-reliant biopharma ecosystem

As global demand for advanced therapeutics continues to rise, India's investments in research, talent, and infrastructure are expected to position the country as a key player in the next generation of healthcare solutions.